SML3656
PAPTP trifluoroacetate
≥98% (HPLC)
别名:
(3-(4-(4-((7-Oxo-7H-furo[3,2-g]benzopyran-4-yl)oxy)butoxy)phenyl)propyl)triphenyl phosphonium trifluoroacetate, (3-(4-(4-(7-Oxo-7H-furo[3,2-g]chromen-4-yloxy)butoxy)phenyl)propyl)triphenylphosphonium trifluoroacetate
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C42H38O5P · xC2HF3O2
分子量:
653.72 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
Quality Segment
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
storage temp.
-10 to -25°C
SMILES string
O=C1C=CC2=C(C3=C(C=C2O1)OC=C3)OCCCCOC4=CC=C(C=C4)CCC[P+](C5=CC=CC=C5)(C6=CC=CC=C6)C7=CC=CC=C7
InChI
1S/C42H38O5P/c43-41-25-24-37-40(47-41)31-39-38(26-29-45-39)42(37)46-28-11-10-27-44-33-22-20-32(21-23-33)13-12-30-48(34-14-4-1-5-15-34,35-16-6-2-7-17-35)36-18-8-3-9-19-36/h1-9,14-26,29,31H,10-13,27-28,30H2/q+1
InChI key
MHIFCBNYOHOSHK-UHFFFAOYSA-N
Biochem/physiol Actions
Kv1.3-selective, mitochondria-targeting Kv1.3 blocker that induces ROS-mediated cancer-selective killing both in vitro and in vivo. More effective than PAP-1.
PAPTP is a PAP-1-derivatized Kv1.3-selective potassium channel blocker with a positively charged lipophilic propyl-triphenylphosphonium (TP) moiety that allows mitochondria-targeted PAPTP delivery. Mitochondria Kv1.3 inhibition induces oxygen species (ROS)-mediated cancer-selective killing both in cultures (by 28%/69%/95% post 24-hr 0/1/10 µM PAPTP treatment of primary B-CLL; 20%/24% normal B-cell death with 0/20 µM PAPTP) and in murine orthotopic models of melanoma and pancreatic ductal adenocarcinoma in vivo (5 µmol/kg q.o.d. via i.p.). PAPTP exhibits higher anti-cancer efficacy than PAP-1 both in vitro and in vivo, and and is less affected by ultidrug resistance (MDR).
Disclaimer
Hygroscopic
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML3656-25MG | 04065269801634 |
| SML3656-5MG | 04065269801641 |